By Deena Beasley (Reuters) -Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including$39 million for its new prevention drug Yeztugo, helping to boost its profit. The company's overall product sales, however, fell 2% to $7.3 billion due to lower COVID-19 and cell therapy sales. Shares of Gilead, which closed down a fraction, were down 3.5$114.30 in after-hours trading. Wall Street expected sales of Yeztugo, which has an annual U.S. list price of ab ...